These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23953880)

  • 1. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
    Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
    Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
    Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
    Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
    Guo G; Kang Q; Zhu X; Chen Q; Wang X; Chen Y; Ouyang J; Zhang L; Tan H; Chen R; Huang S; Chen JL
    Oncogene; 2015 Apr; 34(14):1768-79. PubMed ID: 24837367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking miRNA regulation to BCR-ABL expression: the next dimension.
    Faber J; Gregory RI; Armstrong SA
    Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
    Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
    Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
    Stein AM; Bottino D; Modur V; Branford S; Kaeda J; Goldman JM; Hughes TP; Radich JP; Hochhaus A
    Clin Cancer Res; 2011 Nov; 17(21):6812-21. PubMed ID: 21903771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
    Gómez-Casares MT; García-Alegria E; López-Jorge CE; Ferrándiz N; Blanco R; Alvarez S; Vaqué JP; Bretones G; Caraballo JM; Sánchez-Bailón P; Delgado MD; Martín-Perez J; Cigudosa JC; León J
    Oncogene; 2013 Apr; 32(17):2239-46. PubMed ID: 22710719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
    Leo E; Mancini M; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
    J Cell Biochem; 2015 Apr; 116(4):589-97. PubMed ID: 25389112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.